These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38706978)

  • 1. Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060.
    Tozuka T; Minegishi Y; Yamaguchi O; Watanabe K; Toi Y; Saito R; Nagai Y; Tamura Y; Shoji T; Odagiri H; Ebi N; Sakai K; Kanaji N; Izumi M; Soda S; Watanabe S; Morita S; Kobayashi K; Seike M
    JTO Clin Res Rep; 2024 Apr; 5(4):100655. PubMed ID: 38706978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
    Takamori S; Komiya T; Powell E
    Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
    Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
    Front Immunol; 2022; 13():875488. PubMed ID: 35693805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracranial radiotherapy with or without immune checkpoint inhibition for brain metastases: a systematic review and meta-analysis.
    He Q; Zhang C; Tang S; Li J; Ren Q
    Transl Cancer Res; 2020 Oct; 9(10):5909-5924. PubMed ID: 35117204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis.
    Qiu L; Gao S; Du S; Sun S; Liang Y; Sun Z; Li T; Jia G; Li K; Sun X; Jiao S; Zhao X
    Front Oncol; 2022; 12():974227. PubMed ID: 36523994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
    Pang LL; Gan JD; Huang YH; Liao J; Zhuang WT; Ali WA; Hong SD; Zhang L; Fang WF
    BMC Cancer; 2023 Jan; 23(1):72. PubMed ID: 36670414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Guo T; Chu L; Chu X; Yang X; Li Y; Zhou Y; Xu D; Zhang J; Wang S; Hu J; Chu Q; Moran T; Cho WC; Merrell KW; Rizzo S; Liu Y; Ni J; Zhu Z
    Transl Lung Cancer Res; 2022 Feb; 11(2):173-187. PubMed ID: 35280308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
    Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
    Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
    Tsukita Y; Tozuka T; Kushiro K; Hosokawa S; Sumi T; Uematsu M; Honjo O; Yamaguchi O; Asao T; Sugisaka J; Saito G; Shiihara J; Morita R; Katakura S; Yasuda T; Hisakane K; Miyauchi E; Morita S; Kobayashi K; Asahina H
    JAMA Oncol; 2024 Apr; 10(4):439-447. PubMed ID: 38451530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.
    Wei Q; Deng T; Wu J; Zeng H; Qi C; Tan S; Zhang Y; Huang Q; Pu X; Xu W; Li W; Tian P; Li Y
    BMC Cancer; 2024 Mar; 24(1):393. PubMed ID: 38549044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor Karnofsky performance status is not a contraindication for neurosurgical resection in patients with lung cancer brain metastases: a multicenter, retrospective PSM-IPTW cohort study.
    Liang L; Wen L; Qin S; He Z; Lu J; Cui R; Jiang X; Hu H; Zhong S; Li C; Yu C; Xie Y; Wang Z; Duan H; Mou Y
    J Neurooncol; 2023 Apr; 162(2):327-335. PubMed ID: 36940052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.
    Metro G; Gili A; Signorelli D; De Toma A; Garaffa M; Galetta D; Economopoulou P; Friedlaender A; Jimenez B; Collazo-Lorduy A; Addeo A; Chiarini P; Costa C; Mountzios G; Roila F
    Clin Transl Oncol; 2021 Sep; 23(9):1818-1826. PubMed ID: 33728869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases.
    Sun C; Zhou F; Li X; Zhao C; Li W; Li J; Xiong A; Yu J; Gao G; Wang Q; Wu F; Zhou C
    Onco Targets Ther; 2020; 13():12777-12786. PubMed ID: 33363383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved survival outcome with not-delayed radiotherapy and immediate PD-1/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases.
    Yu Y; Chen H; Tian Z; Zhang Q; Shui Y; Shen L; Hu Q; Huang Z; Zhu S; Jiang H; Wei Q
    J Neurooncol; 2023 Oct; 165(1):127-137. PubMed ID: 37848757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant immune checkpoint inhibitor treatment + chemotherapy (vs. chemotherapy alone) for locally advanced non‑small cell lung cancer: A retrospective cohort study.
    Yang Y; Liu Z
    Oncol Lett; 2023 Jul; 26(1):292. PubMed ID: 37274484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.